Dosage and Administration
Cycloferon has a convenient dosage scheme. The medicine is available in several forms - tablets and injection. It is taken once a day according to the scheme indicated in the instructions, preferably in the morning before meals. For more information please refer to the description.
Despite the fact that Cycloferon is a potent drug, it has good tolerance and very few side effects. Instructions inform that the risk of adverse reactions increases if the doses of the medicine are not observed or if the drug is taken in the presence of contraindications in the anamnesis.
Like on any antiviral agent, there are some restrictions on the use of Cycloferon:
- Decompensatory stage of liver cirrhosis;
- Pregnancy and lactation;
- Children under 4 years old;
- Individual intolerance to the composition of the drug.
The drug is prescribed with caution to people with a history of gastrointestinal diseases, severe kidney, liver pathology, or an allergy to interferon drugs.
In 2004, the group of scientists and specialists who created the drug was awarded the Prize of the Russian Government “For the Development and Implementation of Cycloferon in Medical Practice".
Cycloferon has no structural analogues, i.e. drugs that have the same composition as the indicated drug. The list of drugs that have a different composition, but the same principle of action, is quite extensive.
It is important to note that Cycloferon is a powerful drug with a wide spectrum of action. It can be prescribed for serious diseases of a viral nature, including herpes infections, hepatitis and other pathologies, while many analogues are only used for treatment and prevention of influenza and colds. It is also necessary to remember that many drugs are not prescribed for children, while Cycloferon is suitable for use from 4 years old.
Before administering any of the drugs, it is important to familiarize yourself with the instructions, and consult a doctor.
Cycloferon is a drug that has been used in the pharmacological practice for over 20 years, since 1992. Its widespread use is due to its effective antiviral and immunomodulating activity and the lack of adverse reactions.
The active ingredient is meglumine acridone acetate, which is effective against not only viruses, but also bacteria and fungi. Meglumine acridone acetate is an inducer of endogenous interferon, which has an antiviral, immunomodulating effect, as well as anti-inflammatory, antiproliferative and antitumor effects.
Due to such properties of the drug, it is supposed to perform the following functions in the human body:
- Activate bone marrow stem cells;
- Activate killer cells and T-lymphocytes;
- Normalize the immune status in HIV-infected people;
- Exhibit antimicrobial and antichlamydial action;
- Prevent the development of tumor processes in the body;
- Suppress autoimmune reactions;
- Improve the balance of immunity;
- Inhibit the growth and development of pathogenic viruses, bacteria.
Due to the wide spectrum of action of Cycloferon, it is used not only for the treatment and prevention of acute viral infections, but also in the treatment of other diseases, including oncology.
Cycloferon is included in the List of Essential and Important Medicines in the Russian Federation, as well as in the treatment standards for influenza of varying severity, both in adults and in children. The effect of the drug has been proven and adverse reactions are being monitored in all countries where the drug is registered. Over 200 experimental, clinical and scientific publications have been published on Cycloferon.
Its effectiveness and safety have been confirmed in multicenter randomized clinical, pharmacoeconomic and post-registration studies. The drug does not adversely affect vital organs, in particular the liver, because it is not metabolized in it. It does not accumulate in the body and is excreted by the kidneys in the unchanged form within a day after an administration.
The drug shows good tolerability in children. Numerous randomized clinical studies have shown the epidemiological significance and prevention efficacy of Cycloferon, which is manifested in a decrease of the incidence.
- Ivanov SD et al (1999). The use of Cycloferon in experimental radiotherapy of tumors. https://www.ncbi.nlm.nih.gov/pubmed/10443234
- Sukhinin VP et al (2000). Protective effect of Cycloferon in experimental influenza. https://www.ncbi.nlm.nih.gov/pubmed/11107650
- Aznabaev MT et al (2003). Use of Cycloferon in a combined treatment of chlamydial conjunctivitis. https://www.ncbi.nlm.nih.gov/pubmed/12608044
- Gromov SA et al (2003). Neuroimmunopathological mechanisms of preclinical epileptogenesis and their correction by Cycloferon. https://www.ncbi.nlm.nih.gov/pubmed/14763254
- Sologub TV et al (2009). Cycloferon, as an agent in the therapy and urgent prophylaxis of influenza and acute respiratory tract viral infection (multicentre randomized controlled comparative study. https://www.ncbi.nlm.nih.gov/pubmed/20201401
- Grigorian SS et al (2010). Effectiveness of Cycloferon liniment in a complex treatment, and monitoring of cytokine profile of gingival fluid of patients with paradontitis. https://www.ncbi.nlm.nih.gov/pubmed/21207889
- Sukhanov DS et al (2012). An experimental study of the efficiency of Cycloferon in the complex chemotherapy of generalized drug-resistant tuberculosis. https://www.ncbi.nlm.nih.gov/pubmed/23156086
- Malyĭ VP et al (2013). Cycloferon therapy of acute and chronic virus hepatitis C. https://www.ncbi.nlm.nih.gov/pubmed/24738241
- Lialikau S et al (2013). Efficiency of Cycloferon application in often ill children in the period of raised seasonal morbidity of acute respiratory infections. https://www.ncbi.nlm.nih.gov/pubmed/23388533
- Lialikov SA et al (2013). Effect of Cycloferon on tonsils microflora in often ill children. https://www.ncbi.nlm.nih.gov/pubmed/23767101
- Demchenko EV et al (2013). Cycloferon in complex therapy management of chronic laryngitis. https://www.ncbi.nlm.nih.gov/pubmed/24757822
- Yermak SY et al (2014). Cycloferon therapy of chronic gastroduodenitis in children. https://www.ncbi.nlm.nih.gov/pubmed/25975104
- Utkina TM et al (2014). Cycloferon biological activity characteristics. https://www.ncbi.nlm.nih.gov/pubmed/25286535
- Stelmakh VV et al (2014). Pulmonary vasculitis as a clinical mask of HCV infection: efficiency of interferon-free antiviral therapy. https://www.ncbi.nlm.nih.gov/pubmed/25715495
- Isakov VA, Isakov DV (2015). Immunomodulators in the treatment and prevention of herpes virus infections. https://www.ncbi.nlm.nih.gov/pubmed/26155705
- Soboleva LA et al (2015). Efficacy of Cycloferon liniment in the combined treatment of chronic gingivitis in patients with chronic infectious diseases. https://www.ncbi.nlm.nih.gov/pubmed/26591207
- Mazina N et al (2018). Clinical efficiency of Cycloferon in children and adults with HIV and/ or herpes infection: systematic review and meta-analysis. https://www.ncbi.nlm.nih.gov/pubmed/30358555